| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 1,080 | 1,380 | 1,590 | 900 | 1,010 |
| Sales Growth | -21.74% | -13.21% | +76.67% | -10.89% | unch |
| Net Income | -20,060 | -15,450 | -14,290 | -8,940 | -7,530 |
| Net Income Growth | -29.84% | -8.12% | -59.84% | -18.73% | -76.76% |
Cyclo Therapeutics Inc (CYTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cyclo Therapeutics Inc. is a clinical-stage biotechnology company. It develops cyclodextrin-based products for the treatment of disease. The company's Trappsol(R) Cyclo(TM), an orphan drug designated product primarily in the United States and Europe, is in ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. Cyclo Therapeutics Inc., formerly known as CTD Holdings Inc., is based in ALACHUA, Fla.
Fiscal Year End Date: 12/31